Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged anda · clear
VALEANT PHARMACEUTICALS INTL. v. MYLAN PHARMACEUTICALS INC. Before Lourie, Reyna, and Hughes. Appeal from the United States District Court for the District of New Jersey. Summary: Prior art ranges for solutions of structurally and functionally similar…
Federal Circuit Summary Before Lourie , Dyk, and Taranto. Appeal from the District Court for the District of Delaware. Summary : A passing reference in the prior art to a formulation containing the claimed active ingredient and the claimed administration…
Federal Circuit Summary Before Prost, Lourie and Hughes. Appeal from the United States District Court for the District of Delaware. Summary : When another patent for a drug issues after an ANDA is filed, there can still be jurisdiction for an infringement…
Written by Jane Xia and Jing Liu, Ph.D. MILLENNIUM PHARMACEUTICALS, INC. v. SANDOZ INC (Fed. Cir. July 17, 2017) (NEWMAN, Mayer, O’Malley) This case arose out of an ANDA litigation between Millennium and a number of generic-drug companies who sought…
Written by Peter Heuser, Schwabe Williamson & Wyatt In Shire , the panel rejects defendant’s attempt to read “consisting of” as though the claims read “consisting essentially of.” While we normally limit our comments to…
In Intendis v Glenmark , the Federal Circuit affirmed a finding of infringement under the doctrine of equivalents based on statements made by Glenmark to the FDA. The issue was whether isopropyl myristate in Glenmark’s formulation was equivalent to…
